| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Castle Biosciences, Inc.$24.53
+0.51 (+2.12%)
C 41Pipeline Score Diagnostics · Commercial
Market Cap
611.15 M
EPS
-0.43
P/E Ratio
-
Value Trade
10.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
83.68 M
R&D Expenses
14.43 M
Operating CF
-22.13 M
Total Assets
547.80 M
Total Liabilities
86.39 M
Equity
461.42 M
D/E Ratio
12,345
7.81 %
Week
-18.49 %
1 Month
-36.25 %
3 Month
-43.56 %
6 Month
-65.98 %
5 Year
0.75 %
All Time
Cash Data
Cash Position
261.69 M
Monthly Burn
7.38 M
Runway
33.3 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
102.33 K
52 Week Range
14.59 - 44.28
% held by Insiders
2.58 %
% held by Institutions
90.97 %
Enterprise Value
386.19 M
Total Shares
30.32 M
Short %
5.05 %
Float Shares
28.35 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Castle Biosciences, Inc.
265Total events
1Upcoming
24Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
▲Other Regulator MilestoneAdvanceAD-TxEx-US Regulatory
Subscribe to view catalyst details
TBD
▲Enrollment MilestoneTissueCypherTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C41
Pipeline Score $464M
Pipeline ValueValuation Signal
6
Drugs Scored0.8x
rNPV / MCap Top 59%
Micro Cap (rank 375 of 912)
Percentile RankCastle Biosciences, Inc. carries a moderate pipeline score (41/100), with $1.2B risk-adjusted pipeline value, led by Berberine in Schizophrenia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Berberine Small molecule | Schizophrenia | Phase 2 | NCT02983188 | 43% | $377M | COMPLETED | 113 | - | - | Jan 4, 2021 | - | Jan 22, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DecisionDx-Melanoma | cutaneous melanoma | — | 2026-03-30 | five-year MSS was 96.7% for those with low-risk (Class 1A) results versus 70.0% for high-risk (Class 2B) results; MSS was 87.4% for low-risk versus 48.5% for high-risk results Read More | Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 Read More | |
DecisionDx-Melanoma | cutaneous melanoma | — | 2026-03-30 | five-year MSS was 96.7% for those with low-risk (Class 1A) results versus 70.0% for high-risk (Class 2B) results; MSS was 87.4% for low-risk versus 48.5% for high-risk results Read More | Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 Read More | |
DecisionDx-Melanoma | cutaneous melanoma | — | 2026-03-30 | five-year MSS was 96.7% for those with low-risk (Class 1A) results versus 70.0% for high-risk (Class 2B) results; MSS was 87.4% for low-risk versus 48.5% for high-risk results Read More | Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CSTL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CSTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CSTL▲ +2.1%today
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Castle Biosciences has received approval from the New York State Department of Health for its AdvanceAD-Tx test, designed to guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. This non-invasive test analyzes gene expression from skin samples to classify patients into molecular profiles, helping clinicians select the most effective therapies. The approval enhances patient access to this innovative diagnostic tool in New York.
Read more →CSTLCastle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Castle Biosciences, Inc. will announce its second quarter financial results for 2026 on July 30, 2026, after market close. A webcast will follow at 4:30 p.m. Eastern time, allowing stakeholders to discuss the results. The company emphasizes its commitment to innovative diagnostics in patient care.
Read more →CSTL▲ +6.1%on this news
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
A new study reveals that Castle Biosciences' DecisionDx-Melanoma i31-SLNB test outperforms the MIA nomogram in predicting sentinel lymph node (SLN) positivity in melanoma patients. The i31-SLNB test identified low-risk patients with a 2.6% SLN positivity rate, significantly below the NCCN threshold. This advancement aids clinicians in making informed decisions regarding SLNB procedures.
Read more →CSTLCastle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Frank Stokes, CFO of Castle Biosciences, has been honored as a 2026 CFO Awards honoree by the Houston Business Journal. He is recognized for his financial leadership and contributions to the company's success. Stokes has been with Castle since 2017 and played a key role in its IPO and strategic growth. The awards event will take place on July 30, 2026.
Read more →CSTLCastle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher Barrett's Esophagus Test has surpassed 100,000 clinical test orders. This AI-derived test predicts the five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, aiding clinicians in personalizing patient management. The milestone reflects increasing adoption and positive patient feedback.
Read more →CSTLFirst Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
SciBase has enrolled the first patient in a clinical study aimed at predicting flare-ups in atopic dermatitis. The DETECT-AD study will utilize Electrical Impedance Spectroscopy to identify early signs of flares, shifting from reactive to proactive treatment approaches. This initiative seeks to improve patient quality of life and reduce the unpredictability of flare-ups.
Read more →CSTLCastle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
Castle Biosciences, Inc. will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The presentation will provide an overview of the company's innovative diagnostics aimed at improving patient care. A live audio webcast will be available, along with a replay post-event. The company specializes in dermatologic and gastroenterological disease management.
Read more →CSTLCastle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences has been awarded the 'Genomics Innovation Award' for its AdvanceAD-Tx test, which aids in treatment decisions for moderate-to-severe atopic dermatitis. This non-invasive test measures gene expression to guide therapy selection, resulting in improved patient outcomes. The award highlights Castle's ongoing commitment to innovation in healthcare technology.
Read more →CSTLCastle Biosciences Reports First Quarter 2026 Results Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 36% over Q1 2025 Ra
Castle Biosciences, Inc. reported strong financial results for Q1 2026, achieving revenues of $83.7 million, despite a decrease from the previous year's figure. The company experienced a 36% increase in test reports for its core products, DecisionDx-Melanoma and TissueCypher, and has raised its full-year revenue guidance for 2026 to between $345-355 million. While the gross margin improved significantly, net cash used in operations saw an increase due to specific one-time costs. The overall results reflect robust execution and confidence in business growth.
Read more →CSTLCastle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. announced it will release its financial results for Q1 2026 on May 6, 2026. The results will be shared after market close, followed by a webcast at 4:30 p.m. ET. This event will include a Q&A session, promoting engagement with investors and stakeholders.
Read more →CSTLCastle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Castle Biosciences has been awarded the 2026 USA TODAY Top Workplaces Award for the fifth consecutive year, highlighting its commitment to a people-first culture. The award is based on employee feedback and reflects the company's dedication to improving patient care. CEO Derek Maetzold emphasized the importance of valuing and empowering team members.
Read more →CSTLCastle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences will present data at the AAD 2026 showing that its DecisionDx-Melanoma test enhances risk stratification for cutaneous melanoma patients. The test identifies significant differences in mortality risk within AJCC stages, allowing for more personalized management. This could lead to better care for high-risk patients while reducing unnecessary interventions for those at lower risk.
Read more →CSTLDecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Recent findings from the largest prospective multicenter study on DecisionDx-Melanoma's i31-SLNB test reveal a 2.6% actual sentinel lymph node (SLN) positivity rate in patients predicted to have less than 5% risk. This supports the test's effectiveness in identifying low-risk patients who may safely avoid unnecessary SLNB procedures. The study highlights the test's role in enhancing decision-making for melanoma management.
Read more →CSTLCastle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle Biosciences will present new data on the DecisionDx-Melanoma's i31-SLNB test at the SSO 2026 Annual Meeting. This test helps identify T1b–T2a melanoma patients who may safely avoid sentinel lymph node biopsy. The data supports the test's role in guiding risk-aligned management decisions consistent with established guidelines.
Read more →CSTLCastle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences has announced the grand opening of its new corporate headquarters in Friendswood, Texas, scheduled for March 24, 2026. The facility aims to foster collaboration and innovation among employees while supporting the company's growth in molecular diagnostics. Local officials will attend the event, highlighting the company's commitment to the community. The new campus features modern workspaces and sustainable design elements.
Read more →CSTLCastle Biosciences Reports Fourth Quarter and Full-Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 37% over 2024 Exceeded 2025 guidance with full-yea
Castle Biosciences reported strong financial results for the fourth quarter and full year of 2025, with total revenues reaching $344 million, exceeding guidance. Key revenue drivers, including DecisionDx-Melanoma and TissueCypher, saw substantial growth, the latter increasing its test reports by 86%. However, the company faced challenges with a net loss of $24.2 million due to several factors, including changes in Medicare coverage and the discontinuation of IDgenetix. Despite these challenges, the outlook for 2026 remains optimistic with expected revenues between $340-350 million.
Read more →CSTL▼ -7.3%on this news
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Castle Biosciences, Inc. will announce its fourth quarter and full-year 2025 financial results on February 26, 2026. The results will be shared after market close, followed by a conference call at 4:30 p.m. ET. Investors can access the call via phone or webcast, with a Q&A session included.
Read more →CSTLcstlq42025prel 2026 Castle Biosciences 1 Empowering people, informing care decisions Preliminary Unaudited Fourth Quarter and Year-End Results 2025 January 2026 2026 Castle Biosciences 2 Disclaimers Forward-Looking State
Castle Biosciences has released preliminary unaudited financial results for the fourth quarter and year-end 2025, highlighting an expected revenue surpassing $340 million. The company also launched a new test, AdvanceAD-Tx, designed for atopic dermatitis patients. However, changes in Medicare coverage announced earlier may affect the volume of tests reported. These results are subject to adjustments based on final audits, which will be disclosed in February 2026.
Read more →CSTLCastle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences, Inc. (CSTL) announced preliminary results for Q4 and FY 2025, expecting total revenues to surpass $340 million. The company's core tests, including DecisionDx-Melanoma and TissueCypher, saw significant growth in reported tests year-over-year. The firm anticipates strong financial standing moving into 2026, bolstered by the recent launch of AdvanceAD-Tx for atopic dermatitis. However, some test volumes experienced a decline, and changes in Medicare coverage may influence future outcomes.
Read more →CSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025
Castle Biosciences announced the granting of restricted stock units (RSUs) to 83 employees as an inducement for their employment. The RSUs, totaling 139,494 shares, will vest over four years, aligning employee retention with company growth. This initiative is part of the company's 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Read more →CSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences, Inc. has granted restricted stock units (RSUs) to 83 employees as part of its 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs, covering 139,494 shares, will vest over four years, incentivizing employee retention. This initiative underscores the company's commitment to enhancing its workforce while focusing on innovative diagnostic solutions.
Read more →CSTLLandmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Castle Biosciences announced results from a landmark study showing that the combination of DecisionDx-UM and PRAME gene expression analysis outperforms traditional gene mutation analysis in predicting survival outcomes for uveal melanoma patients. This study, the largest of its kind, highlights the importance of precise risk stratification in guiding treatment decisions. The findings support the use of these tests in clinical practice for better patient management.
Read more →CSTLCastle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Castle Biosciences, Inc. (Nasdaq: CSTL) has been acknowledged by the Houston Chronicle as a Top Workplace for the fifth consecutive year. The company has received additional recognition with three Culture Excellence awards in Employee Appreciation, Well-Being, and Professional Development. CEO Derek Maetzold emphasized the importance of their people-first culture, which he believes is crucial for transforming disease management. The organization has also more than doubled its workforce since earning its first Top Workplaces designation in 2021.
Read more →CSTLCastle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Castle Biosciences, a diagnostics company, will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The presentation will provide an overview of the company's innovative tests aimed at improving patient care. A live audio webcast will be available for those unable to attend in person.
Read more →CSTL▲ +21.7%on this news
Castle Biosciences Reports Third Quarter 2025 Results
Castle Biosciences reported strong financial results for Q3 2025, achieving $83 million in revenue and a 67% increase in non-dermatologic revenue compared to the previous year. The company raised its full-year revenue guidance to $327-335 million, highlighting the success of its core tests, including DecisionDx-Melanoma and TissueCypher. Additionally, the launch of AdvanceAD-Tx aims to improve treatment decisions for patients with moderate-to-severe atopic dermatitis.
Read more →CSTL▲ +21.7%on this newsshared move
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Castle Biosciences has launched AdvanceAD-Tx, a gene expression profile test aimed at guiding systemic treatment decisions for patients aged 12 and older with moderate-to-severe atopic dermatitis. The test identifies patients likely to benefit from JAK inhibitors, showing improved outcomes compared to traditional therapies. This launch reflects the company's strategy to address unmet needs in dermatology and is expected to tap into a significant market opportunity.
Read more →CSTLCastle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. announced its participation in the Stephens 27th Annual Investment Conference on November 19, 2025, where the executive management will present a company overview. Additionally, the company will hold one-on-one meetings during the Jefferies Global Healthcare Conference from November 18-20, 2025. The firm focuses on innovative diagnostic tests for various health conditions.
Read more →CSTLNew Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Castle Biosciences presented new data at the ACG 2025 Annual Meeting, showcasing its TissueCypher Barrett's Esophagus test. This test offers risk insights that extend beyond traditional pathology, allowing for personalized clinical management and timely interventions for patients at higher risk of esophageal cancer. The findings emphasize the importance of individualized patient care in managing Barrett's esophagus.
Read more →CSTLNew Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle Biosciences announced the presentation of new data on its DecisionDx-Melanoma test at the Fall Clinical Dermatology Conference. The study, involving 13,560 patients, confirms the test's ability to stratify melanoma risk across different histological subtypes. This finding reinforces the test's clinical value in guiding patient management and treatment decisions.
Read more →CSTLCastle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
Castle Biosciences, Inc. will announce its third quarter financial results on November 3, 2025. Following the release, management will host a conference call and webcast at 4:30 p.m. ET to discuss the results. The company is focused on innovative tests that improve patient care and has a diverse portfolio in diagnostics.
Read more →CSTLCastle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Derek Maetzold, founder and CEO of Castle Biosciences, has been awarded CEO of the Year by The CEO Magazine. This recognition highlights his innovative leadership and commitment to patient care, which has transformed Castle from a startup into a leading diagnostics company. Under his guidance, the company has fostered a strong workplace culture and developed a portfolio of tests for critical health challenges.
Read more →CSTLCastle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Castle Biosciences has been awarded the Greater Pittsburgh Top Workplace for 2025, based on anonymous employee feedback. This recognition reflects the company's strong workplace culture, which prioritizes employee satisfaction and engagement. CEO Derek Maetzold attributes this honor to the dedication of their employees in enhancing patient care. Castle has received multiple accolades this year, showcasing its commitment to a positive work environment.
Read more →CSTLCastle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
Castle Biosciences has been recognized in Newsweek's inaugural list of America's Greatest Companies for 2025. The company was honored for its strong performance in financial strength, workforce dedication, innovation, and commitment to sustainability. CEO Derek Maetzold emphasized the company's dedication to patient care and innovation. This recognition reflects the company's efforts to transform disease management.
Read more →CSTLCastle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 33% over Q2 2024 Rai
Castle Biosciences, Inc. announced its financial results for Q2 2025, reporting a revenue of $86 million and a 33% increase in test reports for its core products. The company has raised its full-year revenue guidance to $310-320 million due to strong performance. However, net income has decreased compared to the same period last year, mainly due to changes in insurance coverage affecting certain tests and the discontinuation of its IDgenetix offering. Notably, the DecisionDx-Melanoma test received Breakthrough Device designation from the FDA, highlighting its clinical value.
Read more →CSTLCastle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences, Inc. has announced that its executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025. The presentation will be accessible via a live audio webcast through the company's website. Castle Biosciences focuses on innovative tests aimed at improving patient care, with a portfolio that includes diagnostics for various cancers and ongoing research in high-need areas.
Read more →CSTLCastle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle Biosciences announced that its founder and CEO, Derek Maetzold, has been named a 2025 Most Admired CEO by the Houston Business Journal. This recognition is awarded to leaders who exhibit strong financial management and contribute positively to workplace culture and community. The event honoring the recipients will take place in August. Under Maetzold's leadership, the company focuses on improving patient outcomes through innovative diagnostic tests for various health conditions.
Read more →CSTL▼ -6.9%on this news
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Castle Biosciences, Inc. has been recognized with several awards in the 2025 Top Workplaces program, including a third consecutive national Healthcare Industry Top Workplaces award and multiple regional and culture excellence awards. The honors affirm the company's strong, people-first culture, which is reflected in employee satisfaction with aspects such as innovation, work-life balance, and leadership. The awards were based on anonymous employee feedback collected via a third-party survey assessing workplace experiences.
Read more →CSTLCastle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Castle Biosciences, Inc. plans to release its financial results for Q2 2025 on August 4, 2025, after market closure. A conference call will be held the same day at 4:30 p.m. Eastern time to discuss the results. The company emphasizes its commitment to improving health through innovative diagnostic tests.
Read more →CSTLCastle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Castle Biosciences has formed a collaboration and license agreement with SciBase to develop diagnostic tests targeting dermatologic diseases, specifically focusing on atopic dermatitis. This partnership will leverage SciBase's Electrical Impedance Spectroscopy technology to create tests that predict flare-ups in patients. The initial development will focus on the U.S. market, with potential expansion to global markets. The deal includes financial arrangements such as royalties and milestone payments contingent on sales performance.
Read more →CSTLCastle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion during the 2025 BIO International Convention. The discussion is set to address the challenges faced by precision medicine companies, focusing on the commercialization of innovative diagnostic tests. The panel aims to explore effective strategies to navigate current market complexities while enhancing patient care. Castle Biosciences is also represented as part of the City of Phoenix and Texas delegations at the convention.
Read more →CSTLCastle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards
Derek Maetzold, founder and CEO of Castle Biosciences, has been honored with a Lifetime Achievement Award by The American Business Awards for his leadership in the healthcare industry. This prestigious recognition highlights his role in establishing Castle Biosciences as a leader in molecular diagnostics and precision medicine. The company is noted for its innovative tests that significantly improve patient care and has achieved accolades such as being named a Top Workplace USA for four consecutive years. The award ceremony is set to take place in New York on June 10, 2025.
Read more →CSTLCastle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Castle Biosciences, Inc. (Nasdaq: CSTL) will present an overview of the company at the 2025 Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be available via a live audio webcast for interested parties. Castle Biosciences focuses on innovative diagnostic tests aimed at improving healthcare outcomes. Their portfolio includes various tests for skin cancers and other significant medical conditions.
Read more →CSTLCastle Biosciences Celebrates Skin Cancer Awareness Month
Castle Biosciences is commemorating Skin Cancer Awareness Month by launching various initiatives to enhance education and awareness regarding melanoma. The company continues its valuable partnerships with organizations such as IMPACT Melanoma and AIM at Melanoma to foster community support. A virtual patient symposium is scheduled to empower newly diagnosed patients and their caregivers. Additionally, patient stories, particularly that of melanoma survivor Leah Adams, will be shared to underline the significance of early detection and personalized risk assessment.
Read more →CSTLCastle Biosciences to Acquire Previse
Castle Biosciences has signed an agreement to acquire Previse, a company focused on gastrointestinal health, particularly chronic acid reflux diseases. This acquisition aims to complement Castle's existing offerings within the gastrointestinal franchise and leverage Previse’s methylation technology for early detection and prevention of related conditions like esophageal cancer. The deal is anticipated to close shortly, contingent on customary conditions, and highlights Castle's dedication to enhancing patient care through innovative testing solutions.
Read more →CSTLCastle Biosciences Reports First Quarter 2025 Results Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, DecisionDx -SCC, TissueCypher
Castle Biosciences reported a robust financial performance for Q1 2025, showcasing a 21% revenue growth to $88 million compared to the same quarter in 2024. The total number of test reports increased significantly, particularly for core revenue drivers, prompting the company to raise its full-year revenue guidance. However, the company did report an increased net loss for the quarter, attributed to non-cash expenses and the discontinuation of the IDgenetix test. Despite these challenges, Castle remains optimistic about its growth trajectory and clinical impact.
Read more →CSTLCastle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences, Inc. announced it will release its first quarter 2025 financial results on May 5, 2025, after market close. Management will host a conference call at 4:30 p.m. Eastern Time the same day to discuss the results. The company focuses on innovative diagnostic tests that enhance patient care and has a diverse portfolio targeting multiple health conditions. Access details for the call and webcast were provided in the announcement.
Read more →CSTLCastle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences, Inc. (CSTL) is enhancing efforts to raise awareness for esophageal cancer during Esophageal Cancer Awareness Month in April. The company is collaborating with prominent organizations like ECAN and AFS to promote education and prevention initiatives. Emphasizing the critical need for early detection, Castle leverages its risk-stratification test, TissueCypher®, to help identify patients most at risk of progressing to cancer. The initiatives include a digital media campaign and collaborative podcast episodes aimed at increasing awareness and encouraging early screening.
Read more →CSTLCastle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Castle Biosciences, Inc. has been awarded the Top Workplaces USA award for the fourth consecutive year, ranking 30th among 358 U.S. companies with 500-999 employees. This recognition is based solely on employee feedback gathered through a national survey. Castle's high participation rate of 95% and engagement score of 85% indicate a strong commitment to its employee culture. The award underscores the company's mission to foster a supportive and innovative workplace environment.
Read more →CSTLCastle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx -Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle Biosciences will present data on its DecisionDx-Melanoma test at the EADO Congress in Athens, illustrating its effectiveness in risk stratification for melanoma patients. The test helps guide adjuvant therapy and imaging surveillance for those at higher risk of metastasis, particularly to the central nervous system. Findings indicate that using the DecisionDx-Melanoma test can lead to better personalized treatment plans, which may improve patient outcomes.
Read more →CSTLCastle Biosciences' DecisionDx -SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Castle Biosciences announced that its risk-stratification test, DecisionDx-SCC, received a top five abstract recognition at the NCCN 2025 Annual Conference. New data from a cohort of 1,412 high-risk squamous cell carcinoma patients indicate that the test enhances metastatic risk prediction beyond traditional staging methods. Additionally, the DecisionDx-Melanoma test demonstrated its role as a significant predictor of mortality in nearly 7,000 patients with early-stage cutaneous melanoma. These findings underscore the tests’ value in guiding more personalized treatment pathways for clinicians.
Read more →CSTLCastle Biosciences Reports Fourth Quarter and Full-Year 2024 Results Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports
Castle Biosciences reported strong financial results for the fourth quarter and full year 2024, with revenues of $332 million, a 51% increase from the previous year. Total test reports delivered rose by 36% to 96,071. The company is optimistic about its performance, anticipating revenues of between $280-295 million in 2025. Key achievements include enhancements in dermatologic tests and receiving assay approval for its TissueCypher Barrett's Esophagus test, boosting its operational capabilities.
Read more →CSTLCastle Biosciences Reports Third Quarter 2024 Results Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 mi
Castle Biosciences reported significant growth in Q3 2024, with revenues increasing by 39% year-over-year to $86 million and total test reports rising by 41%. The company has also raised its full-year revenue guidance for 2024 to between $320 million and $330 million, up from previous estimates of $275 million to $300 million. The increased revenue and operational improvements reflect successful growth initiatives and expanding clinical evidence supporting their tests. The company expressed optimism about its future prospects based on this strong performance.
Read more →CSTLCastle Biosciences Reports Second Quarter 2024 Results Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 m
Castle Biosciences reported strong second-quarter results for 2024, with revenues reaching $87 million, up 74% from the previous year. The company also noted a 49% increase in total test reports delivered. Citing robust growth, Castle has increased its full-year revenue guidance to between $275 million and $300 million. Additionally, their DecisionDx-SCC test has achieved recognition through a significant study that highlights its effectiveness in guiding treatment recommendations for skin cancer patients.
Read more →CSTLCastle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $ 255-265 m
Castle Biosciences reported impressive financial results for the first quarter of 2024, with revenues rising by 74% year-over-year to $73 million. The total number of test reports also grew by 40% compared to the same period in the previous year. The company has raised its full-year revenue guidance to between $255 million and $265 million, reflecting confidence in ongoing demand for its innovative testing solutions. Additionally, significant recent studies highlighted the clinical utility and economic benefits of their tests, particularly regarding cost savings for Medicare.
Read more →CSTLCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports
Castle Biosciences reported a substantial revenue increase of 60% year-over-year for 2023, totaling $220 million. The company delivered over 70,000 test reports, with particular growth in the DecisionDx-Melanoma test. Two new peer-reviewed publications underscored the test's positive impact on patient outcomes. Despite these positive developments, Castle reported a net loss of $57.5 million for 2023, a slight improvement compared to the previous year.
Read more →CSTL▲ +6.1%on this news
Castle Biosciences Reports Third Quarter 2023 Results Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $2
Castle Biosciences, Inc. reported strong financial results for Q3 2023, with revenue increasing by 66% to $61 million compared to Q3 2022. The company also saw a significant rise in total test reports, up 52%, contributing to their decision to raise full-year revenue guidance to at least $200 million. Despite the positive growth, the company reported a net loss of $(6.9) million, although this was an improvement from the previous year. The ongoing investments in their test portfolio are aimed at enhancing patient care and supporting long-term value creation.
Read more →CSTLCastle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $
Castle Biosciences reported a strong performance for the second quarter of 2023, with revenues reaching $50.1 million, a 44% year-over-year increase. The company also raised its full-year revenue guidance to a minimum of $180 million following a 52% increase in total test reports. Key tests such as DecisionDx-Melanoma and DecisionDx-SCC have shown significant clinical value, contributing to growth. Despite the positive financial indicators, the company faced increased net losses during the quarter.
Read more →CSTL▲ +26.2%on this news
Castle Biosciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm has launched an investigation for investors of Castle Biosciences, Inc. who lost money on their stocks. The firm is seeking potential claims based on allegations of misleading statements or undisclosed information by the company. Investors are encouraged to reach out for a complimentary case evaluation to explore their legal rights and options for recovery.
Read more →CSTLCastle Biosciences Reports First Quarter 2023 Results Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be b
Castle Biosciences reported robust financial results for Q1 2023, with revenues rising by 57% to $42 million and total test reports soaring by 73% compared to the previous year. The company reaffirmed its full-year revenue guidance between $170-180 million, reflecting strong momentum and execution of their growth strategies. Despite this growth, the company faced a net loss of $29.2 million and negative adjusted EBITDA of $15.1 million, indicating ongoing financial challenges.
Read more →CSTLCastle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase o
Castle Biosciences reported a strong financial performance for 2022, with revenues increasing by 46% to $137 million and total test reports rising by 58%. The company expects revenues in 2023 to be between $170-180 million, backed by ongoing initiatives to expand its test offerings and integrate recent acquisitions. Despite the positive revenue growth, the company faced a net loss of $(67.1) million and reported negative operating cash flow. Nonetheless, management remains optimistic about the foundation laid for future growth, highlighting their team's execution.
Read more →CSTLDocument Castle Biosciences Announces Third Quarter 2022 Results Q3 2022 revenue grew by 58% over Q3 2021 to $37.0 million Delivered 12,114 total test reports in Q3 2022, an increase of 57% compared to Q3 2021 Foundation
Castle Biosciences Announces Third Quarter 2022 Results Q3 2022 revenue grew by 58% over Q3 2021 to $37.0 million Delivered 12,114 total test reports in Q3 2022, an increase of 57% compared to Q3 2021 Foundational guideposts and three-year financial targets presented at Invest
Read more →CSTL▼ -6.8%on this news
Document Castle Biosciences Reports Second Quarter 2022 Results Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021 Skin canc
Castle Biosciences Reports Second Quarter 2022 Results Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021 Skin cancer gene expression profile test report volume increased 44% compar
Read more →CSTL▼ -8%on this news
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Cast
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. ("Castle" or the "Company") and Cerno
Read more →CSTL▼ -9.4%on this news
Castle Biosciences Reports First Quarter 2022 Results Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in
Castle Biosciences Reports First Quarter 2022 Results Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in Q1 2022, an increase of 68% compared to Q1 2021 Decisio
Read more →CSTLCastle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2
Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2022 revenue is expected to be between $115-120 million C
Read more →CSTLCastle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenu
Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast
Read more →CSTLCastle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports incr
Castle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports increased 70%, compared to Q2 2020 Raising 2021 Revenue Guid
Read more →CSTLCastle Biosciences Announces First Quarter 2021 Results Q1 2021 revenues of $22.8 million, compared to $17.4 million in Q1 2020 Q1 2021 total dermatology test report volume of 4,805 Initiates 2021 Revenue Guidance of $80
Castle Biosciences Announces First Quarter 2021 Results Q1 2021 revenues of $22.8 million, compared to $17.4 million in Q1 2020 Q1 2021 total dermatology test report volume of 4,805 Initiates 2021 Revenue Guidance of $80-83 million Q1 2021 gross margin of 87% Conference call
Read more →CSTLCastle Biosciences Announces Fourth Quarter and Full-Year 2020 Results Full-year 2020 revenues of $62.6 million, up 21% compared to 2019 Full-year 2020 dermatology test report volume up 8% compared to 2019 Full-year 2020
Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results Full-year 2020 revenues of $62.6 million, up 21% compared to 2019 Full-year 2020 dermatology test report volume up 8% compared to 2019 Full-year 2020 gross margin of 85% Earlier today, the Company launched
Read more →CSTLCastle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock FRIENDSWOOD, Texas - Dec. 14, 2020 - Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditio
Read more →CSTLCastle Biosciences Announces Third Quarter 2020 Results Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million DecisionDx-Melanoma report volume returned to quarterly year-over-year increase Q3 2020 gro
Castle Biosciences Announces Third Quarter 2020 Results Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million DecisionDx-Melanoma report volume returned to quarterly year-over-year increase Q3 2020 gross margin of 84% Recently received final expanded positi
Read more →CSTLCastle Biosciences Announces Second Quarter 2020 Results Q2 2020 revenues of $12.7 million, compared to $10.7 million in Q2 2019 DecisionDx-Melanoma test report volume decreased 19% compared to Q2 2019 Gross margin of 83
Castle Biosciences Announces Second Quarter 2020 Results Q2 2020 revenues of $12.7 million, compared to $10.7 million in Q2 2019 DecisionDx-Melanoma test report volume decreased 19% compared to Q2 2019 Positive operating cash flow FRIENDSWOOD, Texas- August 10, 2020--Castle B
Read more →CSTLCastle Biosciences Announces First Quarter 2020 Results Q1 2020 DecisionDx-Melanoma test report volume increased 42% compared to Q1 2019 Q1 2020 revenues of $17.4 million, compared to $8.7 million in Q1 2019, an increase
Castle Biosciences Announces First Quarter 2020 Results Q1 2020 DecisionDx-Melanoma test report volume increased 42% compared to Q1 2019 Q1 2020 revenues of $17.4 million, compared to $8.7 million in Q1 2019, an increase of 100% Operating cash flow for Q1 2020 was $(0.3) milli
Read more →CSTLCastle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases
- Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needs - - Pipeline led by Phase 3 gene therapy candidate for treatment of recessive dystrophic epidermolysis bullosa (RDEB), with a
Read more →CSTLCastle Biosciences Announces Fourth Quarter and Full-Year 2019 Results Q4 2019 recognized revenues of $17.6 million, compared to $11.4 million in Q4 2018 Q4 2019 adjusted revenues of $17.6 million, compared to $6.2 milli
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results Q4 2019 recognized revenues of $17.6 million, compared to $11.4 million in Q4 2018 Q4 2019 adjusted revenues of $17.6 million, compared to $6.2 million in Q4 2018 Full-year 2019 revenues of $51.9 million, c
Read more →CSTLCastle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 Q4 2019 DecisionDx-Melanoma test report volume increase
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 Q4 2019 DecisionDx-Melanoma test report volume increased 37% compared to Q4 2018 Full-year 2019 DecisionDx-Melano
Read more →CSTLCastle Biosciences, Inc. (Q3 2019 Earnings)
Frank Stokes Castle Biosciences CFO Derek Maetzold Castle Biosciences President CEO Catherine Schulte Robert W. Baird Co. Senior Research Analyst, VP Sung Ji Nam BTIG Research Analyst Puneet Souda SVB Leerink Analyst Mark Massaro Canaccord Genuity, LLC Managing Director Ope
Read more →CSTLCastle Biosciences Reports Third Quarter 2019 Results Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 20
Castle Biosciences Reports Third Quarter 2019 Results Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in
Read more →CSTLCastle Biosciences Reports Second Quarter 2019 Results Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018 Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2
Castle Biosciences Reports Second Quarter 2019 Results FRIENDSWOOD, Texas--(BUSINESS WIRE)--September 3, 2019--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2019. "We are pleased with our stron
Read more →CSTLCastle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares FRIENDSWOOD, TEXAS
Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares FRIENDSWOOD, TEXAS, July 29, 2019 - Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the closing of its previously announced initial
Read more →Competitive Position
How CSTL ranks across every disease it competes inCompetitive Position is a premium feature
See how CSTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial